You are here: Industry Insights > Vir Biotechnology

News List

GSK buys stake in Vir Biotechnology in search of Covid-19 therapies pharmaceutical-technology
April 08, 2020
GlaxoSmithKline (GSK) has agreed to invest $250m in Vir Biotechnology for the research and development (R&D) of antibodies to treat Covid-19 infection.
Vir Biotechnology and Alnylam expand alliance for Covid-19 drugs pharmaceutical-technology
April 06, 2020
Vir Biotechnology and Alnylam Pharmaceuticals have expanded their multi-target infectious diseases alliance to include up to three targets for SARS-CoV-2, the novel coronavirus that causes Covid-19.
Xencor, Vir Biotechnology sign licensing deal for Covid-19 pharmaceutical-technology
March 27, 2020
Biopharmaceutical firm Xencor has entered into a technology licence agreement with Vir Biotechnology providing the latter with non-exclusive access to Xtend Fc technology.
Biogen, Vir Enter COVID-19 Antibody Alliance contractpharma
March 16, 2020
Biogen will provide cell line development, process development and clinical manufacturing for Vir's monoclonal antibodies.
Vir Biotechnology and Alnylam partner in fight against Covid-19 pharmaceutical-technology
March 09, 2020
Clinical-stage immunology firm Vir Biotechnology and biopharmaceutical company Alnylam Pharmaceuticals have extended their existing partnership to advance RNAi therapeutics to treat coronavirus infections, including Covid-19.
WuXi Biologics, Vir Biotech Partner to Develop COVID-19 Antibodies contractpharma
March 03, 2020
WuXi Biologics will conduct cell-line development, process and formulation development, and initial manufacturing for clinical development.
WuXi Biologics and Vir Biotechnology Announce Collaboration for Global Development of Antibodies to Treat COVID-19 Wuxi Biologics
February 26, 2020
WuXi Biologics and Vir Biotechnology, Inc. announced a development and manufacturing collaboration to advance and produce human monoclonal antibodies for the potential treatment of Coronavirus Disease 2019 (COVID-19), a disease caused by Severe Acute Resp
Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218 pharmafocusasia
November 28, 2018
Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. announced the initiation of a Phase 1/2 study of VIR-2218, a novel, investigational RNA interference (RNAi) therapeutic for the treatment .......

Previous page 1 2 Next page